Haemophilia care in Asia: Learning from clinical practice in some Asian countries

Pantep Angchaisuksiri,Marilou Amurao‐Abiera,Sheng‐Chien Chou,Pol Chewcharat,Novie Amelia Chozie,Roy Gomez,Tien Sim Leng,Pei‐Chin Lin,Nguyen Thi Mai,Zulaiha Muda,Tulika Seth,Darintr Sosothikul,Raymond Siu‐Ming Wong

DOI: https://doi.org/10.1111/hae.14998

2024-03-25

Haemophilia

Abstract:Background The healthcare systems in Asia vary greatly due to the socio‐economic and cultural diversities which impact haemophilia management. Methods An advisory board meeting was conducted with experts in haemophilia care from Asia to understand the heterogeneity in clinical practices and care provision in the region. Findings The overall prevalence of haemophilia in Asia ranges between 3 and 8.58/100,000 patients. Haemophilia A was more prevalent as compared to haemophilia B with a ratio of around 5:1. There is under‐diagnosis in the region due to lack of diagnosis, registries and/or lack of appropriate facilities in suburban areas. Most patients are referred to the haematologists by their families or primary care physicians, while some are identified during bleeding episodes. Genetic testing faces obstacles like resource constraints, services available at limited centres and unwillingness of patients to participate. Prophylaxis is offered for people with haemophilia (PWH) with a severe bleeding phenotype. Recombinant factors are approved in most countries across the region and are the preferred therapy. The challenges highlighted for not receiving a high standard of care include patients' reluctance to use an intravenous treatment, poor patient compliance due to frequency of infusions, budget constraints and lack of funding, insurance, availability and accessibility of factor concentrates. Prevalence of neutralizing antibodies ranged from 5% to 20% in the region. Use of immune tolerance induction and bypassing agents to treat inhibitors depends on their cost and availability. Conclusion Haemophilia care in Asia has evolved to a great extent. However, some challenges remain for which a strategic approach along with multi‐stakeholder involvement are needed.

hematology